Effect of oriented or random PEGylation on bioactivity of a factor VIII inhibitor blocking peptide.
Peptides as therapeutic substances are efficient agents in the treatment of several diseases. However, they often have to be chemically modified in order to be suited as therapeutic agent. Conjugation to large carrier molecules is often required. A critical step is the identification of available sites for chemical reaction, without influencing bioactivity. Peptide 238/S1 with the sequence NH(2)-PYWKWQYKYD-COOH previously selected from a combinatorial decapeptide library, has the ability to block inhibitory antibodies against blood clotting factor VIII (FVIII) and therefore, it constitutes a lead for developing a drug to treat patients suffering from development of such antibodies. The aims of this study were (i) to identify sites of the peptide, which are suited for modification without losing bioactivity and (ii) to find out the influence of molecular size of polyethylene glycol (PEG) for bioactivity of the peptide. The contribution of each amino acid residue to biological functionality was investigated by mutational analysis. This method confirmed that the N-terminus is crucial for activity, whereas both lysine residues could be exchanged by other L-amino acids. Using mutational analysis it was possible to identify peptides with higher reactivity compared to the wild type 238/S1. PEGylation experiments demonstrated that conjugation of the peptide to PEG 20,000 resulted in a loss of reactivity, while PEG 5,000 could maintain the bioactivity when conjugated in a site directed manner. The peptide lost its neutralization properties when PEG was coupled to the N-terminus, again indicating that this part of the peptide is important for functionality.
Kopecky
Eva-Maria
EM
Department of Biotechnology, University of Natural Resources and Applied Life Sciences Vienna, Vienna, Austria.
Greinstetter
Sabine
S
Pabinger
Ingrid
I
Buchacher
Andrea
A
Römisch
Jürgen
J
Jungbauer
Alois
A
D000595:Amino Acid Sequence; D005169:Factor VIII / Q000276:immunology* / Q000627:therapeutic use; D006801:Humans; D007074:Immunoglobulin G / Q000276:immunology; D009154:Mutation; D019151:Peptide Library; D010455:Peptides / Q000737:chemistry* / Q000494:pharmacology; D011092:Polyethylene Glycols / Q000737:chemistry*
D007074:Immunoglobulin G; D019151:Peptide Library; D010455:Peptides; D011092:Polyethylene Glycols; D005169:Factor VIII